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Abstract 
Animal and few human studies reveal conflicting results regarding the associations between 
anxiety and the sex steroid hormones, estradiol and progesterone. Natural fluctuations of estradiol 
and progesterone during the menstrual cycle phases have shown to have either an anxiolytic or an 
anxiogenic effect. The present study collected urine samples to analyze levels of estradiol and 
progesterone metabolites (E1G and PdG) from 106 healthy, naturally cycling, Polish women of 
reproductive age. Participants filled out the STAI questionnaires during the entire menstrual cycle, 
but only 18 consecutive days throughout the follicular, mid-cycle, and luteal phases of the whole 
cycle were used for comparisons between women. It was hypothesized that estradiol is 
significantly associated with anxiety during the cycle phases (whole cycle, follicular, mid-cycle, 
and luteal). It was also hypothesized that progesterone is significantly associated with anxiety, 
particularly during the luteal phase and during the mid-cycle phase. Multiple analyses of variance 
(ANOVAs) were conducted to test within-subjects effect of cycle day on anxiety and between 
subjects-effect of estradiol and progesterone on anxiety. No significant within-person or between-
person effect of estradiol or progesterone metabolites emerged, revealing no significant 
associations between the hormones and anxiety levels throughout any of the cycle phases. The 
present results contribute to a growing body of evidence showcasing contradictory results and 
emphasizing the complexity of hormones and our limited understanding of how they impact human 
mood.  
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1. Introduction  
Women are twice as likely as men to experience an anxiety disorder in their lifetime (Andreen et 
al., 2009). Anxiety is an emotion that “functions to keep organisms vigilant to signs of danger” 
(Marks & Nesse, 1994) and is characterized by “tension, apprehension, nervousness, and worry” 
(Spielberger, Gorssuch, Lushene, Vagg, & Jacobs, 1983). Anxiety can have many negative 
impacts on women, including decreased social connectedness, increased perceived threat, higher 
risk for developing physical health issues, and increased co-morbidity with other mental disorders 
such as depression (Booth, Sharma, & Leader, 2016). Anxiety also has economic repercussions to 
those suffering from anxiety to take time off from work which may result in unstable income 
(Booth et al., 2016). Thus, it is important to understand the underlaying causes of anxiety disorders 
and treat them effectively.  
Previous research suggests that there is a relationship between anxiety and fluctuations of 
ovarian hormones during the menstrual cycle (Galeeva, Pivina, Tuohimaa, & Ordyan, 2007). More 
recent studies suggest that response to anxiety may be modulated by the fluctuation of ovarian 
hormones estradiol and progesterone during a woman’s menstrual cycle (Albert, Pruessner, & 
Newhouse, 2015). This project aims to contribute to current research by investigating the 
association between levels of estradiol, progesterone, and subjectively reported anxiety levels 
during the menstrual cycle.  
Both estrogen and progesterone levels change during the menstrual cycle. During the 
follicular phase, estrogen levels slowly rise to reach a sharp peak just before ovulation. After 
ovulation, the ovaries start to release another steroid hormone, progesterone, in preparation for 
pregnancy. During the luteal phase, after the preovulatory drop, estrogen levels rise slowly and 
progesterone peaks, only to fall again at the pre-menstrual phase (Draper et al., 2018). These 
fluctuations in ovarian hormone levels result from a negative feedback loop that includes changes 
of the levels of hypothalamic and pituitary hormones i.e., gonadal releasing hormone (GnRH), 
follicular stimulating hormone (FSH) and luteinizing hormones (LH) (Draper et al., 2018). This 
process indicates that estrogen and progesterone levels are highly associated with one another as 
they tend to co-fluctuate through the menstrual cycle (Graham, Ash, & Den, 2017). Thus, it is of 
interest whether varying levels of these hormones have any links with a woman’s mood or affect, 
in particular anxiety.  
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It is a common notion that ovarian hormone fluctuation during the cycle may have 
emotional and behavioral effects in women. Women are at risk for developing an anxiety disorder 
post pubertally with the beginning of changes in estrogen levels during the menstrual cycle 
(Hayward and Sanborn, 2002). Changes in estrogen levels have been associated with women’s 
susceptibility to anxiety disorders, such as general anxiety disorder, phobias, and post-traumatic 
stress disorder, as well as increased comorbidity with depression (Walf & Frye, 2006). In women, 
both high and low levels of estrogen have been associated with anxiety symptoms (Li & Graham, 
2017), including distorted cognitive processing, hypervigilance, avoidance, and intense emotional 
reactions. Some women with anxiety disorders have reported less anxiety during periods of low or 
stable estrogen levels (Schmidt et al, 1998). However, in female rodents, high estrogen levels have 
been associated with decreased anxiety symptoms, such as increased time spent in a brightly lit 
open field, increased social interaction, and increased immobility in forced swim tests (Walf & 
Frye, 2006).  
Fluctuations of progesterone may also alter anxiety, particularly in the premenstrual phase 
as demonstrated by Backstrom and Carstensen (1974). According to the authors, lower levels of 
progesterone in women were found to be related to negative mood changes and increased anxiety 
during the premenstrual phase. More recent research by Backstrom et al. (2003) concludes that 
there is a relationship between peak luteal progesterone and mood change, however current clinical 
studies are inconsistent in humans. In rodents, progesterone has shown to increase response to 
stress and increase anxiety behaviors, such as foot shock and swim stress (Barbaccia et. al, 1996). 
In humans, luteal phase progesterone has been said to influence the intensity of negative mood 
during the premenstrual phase, with low levels of progesterone linked to lower energy levels and 
aggressive behavior (Ziomkiewicz et al., 2012). This body of evidence suggests that exploration 
of estradiol and progesterone in relation to anxiety may contribute to our understanding of how 
these hormones are associated with human affect.  
 
Animal studies on estradiol, progesterone, and anxiety 
There is conflicting evidence on the effects of estradiol and progesterone on levels of anxiety 
during the menstrual cycle as this topic has been subject to relatively limited investigations in 
humans (Reynolds et al., 2018). Most of our understanding on this topic comes from experimental 
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studies on animals, where single injections are administered to ovariectomized female rodents, 
mostly mice and rats. Studies on the associations between estradiol, progesterone, and anxiety in 
rodents provide evidence for both anxiolytic (i.e. decreasing anxiety) effects and anxiogenic (i.e. 
increasing anxiety) effects of these hormones. One study on single injections of progesterone in 
ovariectomized female mice suggests that an increase in anxiety is associated with an increase in 
progesterone receptor-immunopositve cells in certain brain regions (Galeeva et al., 2007). This 
suggests that progesterone’s role may be to upregulate levels of anxiety (Galeeva et al., 2007). 
Galeeva et al. (2007) also proposed that progesterone injections can have a delayed anxiogenic 
property where anxiety increases sometime after it is administered. Another study on 
ovariectomized female rodents reports that the rats exhibited increased immediate anxiogenic 
behaviors, such as more time spent grooming after receiving an injection with a selective estradiol 
agonist (Lund, Rovis, Chung & Handa, 2005). These animal studies demonstrate that both estradiol 
and progesterone may increase anxiety in rodents after these hormones are administered, thus 
suggesting a link between hormones and mood.  
Other rodent studies report opposing findings. Frye and Walf (2004) found that systemic 
administration of estradiol and progesterone to ovariectomized rats decreased anxiety behaviors in 
females suggesting that these steroid hormones have anxiolytic effects. Furthermore, research of 
estradiol and progesterone priming (i.e. administering of hormone injections) during the proestrus 
(follicular phase) in rodents demonstrated that anxiety would decrease once the rodents were 
injected with the hormones during the follicular phase (Frye and Walf, 2004). These findings 
contradict results from the study by Lund et al (2005) revealing an anxiolytic effect of estradiol 
and progesterone, and point to the importance of considering menstrual cycle phase in relation to 
anxiety and hormones.  
A later study by Walf and Frye (2005) contributed the finding that estradiol’s effects on 
anxiety may be dose-dependent in rodents, and in part is associated with the responsiveness of the 
hypothalamic and pituitary axis. This suggests that different doses administered to the mice 
interplay differently with the HPA axis. It is important to note here that the study was conducted 
on younger and older individuals, thus age was an important factor here. Furthermore, Lund et al. 
(2005) demonstrated in a study how different types of agonists for estradiol have opposing effects 
on anxiety behaviors in rodents (i.e. one type of agonist increased anxiety while another decreased 
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anxiety). Meanwhile, Zeidan et al. (2011) concluded that estradiol induces anxiolytic behavior as 
it enhances the brain’s ability for fear extinction in rodents; however, they did not find evidence 
to support opposing findings as discussed in the previous study stating that estradiol is also 
associated with anxiogenic behaviors. These opposing results presented here suggest that there is 
a need for further research of the role of both estradiol and progesterone during the menstrual cycle 
phases, particularly in relation to anxiety.  
 
Human studies on estradiol, progesterone, and anxiety      
Similar to rodent studies, human studies also report conflicting findings for the roles of estradiol 
and progesterone during the menstrual cycle in relation to anxiety. Estradiol has been reported to 
have opposing effects on mood and HPA axis activity (Weiser et al., 2010). One study on estradiol 
and anxiety demonstrates that this hormone was positively associated with state-trait anxiety and 
attentional bias to threat during periods of higher estradiol, suggesting that anxiety is moderated 
by estradiol (Graham & Shim, 2018). Another study which administered estrogen therapy to 
women reported that the women experienced a decrease of anxiety levels (Gleason et al., 2015). 
This result implies that estrogen may have an anxiolytic effect. However, the study was conducted 
on postmenopausal women and may not be necessarily applicable to women of reproductive age. 
Therefore, research in younger, naturally cycling women of reproductive age is necessary to 
untangle the association between estradiol and anxiety. 
Some human studies also suggest that progesterone can have an anxiolytic effect in women. 
For example, a study on progesterone during the premenstrual period points to the anxiolytic effect 
of high concentration of progesterone during the premenstruum (immediate period before 
menstruation), however the level of anxiety was not directly assessed here (Ziomkiewicz, Wichary, 
Gomula & Pawlowski, 2015). Furthermore, Reynolds et al. (2018) found that women with higher 
average progesterone across phases of their cycle reported higher levels of anxiety than women 
with lower progesterone levels. It was also found that as progesterone levels increased across the 
cycle, so did levels of attachment anxiety (Reynolds et al., 2018). Thus, Reynolds et al. (2018) 
demonstrate the positive association between naturally increasing levels of progesterone levels and 
heightened levels of anxiety. By exploring the cycle phases and how they are associated with 
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progesterone fluctuations, we may be able to understand whether there is a relationship between 
anxiety and progesterone during the menstrual cycle. 
Consideration of these studies showcase how fluctuations of progesterone during the cycle 
phases are associated together and may have the ability to result in either an anxiolytic effect or an 
anxiogenic effect. A delayed anxiogenic effect (e.g. increased anxiety behaviors observed much 
later after hormone injection in rodents) of progesterone was not observed in human studies as was 
in rodent studies discussed previously (Galeeva et al., 2007). Lastly, studies exploring mood 
changes during the menstrual cycle demonstrate that anxiety, irritability, and depression are most 
frequently observed in the luteal phase of the cycle (Davydov, Shapiro, Goldstein, & Chicz-
DeMet, 2005). Once again, the limited studies in humans considering different cycle phases and 
hormone levels suggest a need to explore these relationships. 
 
The need for further research 
As discussed in relevant literature, there is evidence that estradiol and progesterone may alter 
mood. However, the limited research and conflicting evidence as described thus far indicates a 
further need for research on the associations between estradiol, progesterone, and anxiety during 
the menstrual cycle and its phases. The present aims to investigate the association between levels 
of estradiol and progesterone and subjective anxiety during the menstrual cycle. The present study 
hypothesizes that the ovarian steroid hormones estradiol and progesterone are significantly 
associated with self-reported anxiety levels during the menstrual cycle in two ways. The first 
hypothesis is that estradiol (as described by the E1G metabolite) will be significantly associated 
with anxiety scores during the whole cycle, and particularly during the follicular phase. The second 
hypothesis is that progesterone (as described by the PdG metabolite) will be significantly 
associated with anxiety scores during the luteal and during the mid-cycle phase. This will be 
achieved by assessing the relationships between estradiol, progesterone, and anxiety levels in 
women over their menstrual cycle phases and considering the within-person cyclical changes and 
the between-person average hormone differences in hormones. 
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2. Methods 
2.1 Study participants  
A total of 106 women of reproductive age were recruited from the general city population in 
Wroclaw, Poland to participate in a larger study on the relationship between anxiety and sex steroid 
hormone levels. Participants were recruited through announcements placed in newspapers, 
Internet, and a local university. For the purpose of the current study, data from 104 reproductive 
women (age range 24-36) who delivered daily morning urinary samples and completed an anxiety 
questionnaire across one entire menstrual cycle were included. The participants were healthy, 
regularly cycling, and non-obese BMI (range 19-25).  
The following inclusion criteria was used during recruitment: regular menstrual cycle 
length from 24 to 36 days, no use of contraceptives, no pregnancy or lactating for a minimum of 
three months prior to the study, good overall health, and no diagnosed reproductive or 
endocrinological diseases. Women who fit the inclusion criteria were asked to fill in a State-Trait 
Anxiety Inventory. Anthropometric measurements of height, weight, and body composition were 
taken for each participant at the beginning of the study period. In addition, data about participant 
reproductive history, number of children, marital status, education, smoking, and alcohol 
consumption were also collected via general questionnaire. All participants gave written consent 
for their participation in the study. The study was reviewed and approved by the Ministry of 
Science and Higher Education in Poland. The present study was part of a larger project conducted 
by Ziomkiewicz, et al (2012) on temperament and ovarian hormones in women.  
 
2.2 Hormonal analysis 
All participants collected first morning urine samples and filled out the State-Trait Anxiety 
Inventory throughout the entire menstrual cycle. Urine samples were labeled and stored in the 
participant’s home freezers at the lowest temperature (around -20C) for the duration of the 
sampling period. Soon after the last day of the menstrual cycle (last day of collection), samples 
were collected from the participant’s homes and were taken to the Laboratory of Endocrinology, 
Wroclaw Medical University for further analysis. 
The urinary concentration of estradiol (estrone glucuronide, or E1G) and progesterone 
metabolites (pregnanediol glucuronide, or PdG) were analyzed with commercial enzyme 
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immunoassay kits (Siemens Medical Solution Diagnostics, Los Angeles, CA, USA) following 
published producer procedure. E1G and PdG daily values were corrected for concentration 
differences via a method by Miro et al. (2004). Nine daily samples from the follicular phase and 8 
daily samples from the luteal phase were analyzed for E1G and 14 samples from the luteal phase 
were analyzed for PdG. 
 
2.3 Anxiety Assessment 
Anxiety was assessed with the State-Trait Anxiety Inventory (STAI) (Spielberg et al., 1983), a 
validated and widely used questionnaire to operationalize perceived anxiety (Booth et al., 2016). 
The STAI is a psychological inventory based on a four-point Likert scale and consisting of 40 
questions on a self-report basis. The STAI measures two types of anxiety with two scales: state 
anxiety (anxiety about an event) and trait anxiety (anxiety level as a personal characteristic). 
Examples of items in the STAI which participants rated are statements such as “I am tense”, “I 
feel like a failure”, and “I worry too much over something that really doesn’t matter” (Spielberg 
et al., 1983). Alpha coefficients for the Polish version of the STAI (both state anxiety and trait 
scales) scores indicated high internal consistency (Cronbach’s α ranging between .84 and .91). 
 
2.4 Procedure  
Scores for state and trait anxiety were calculated following published procedure (Speilberger et 
al., 1983). The scores were recorded in relation to the days of either the follicular or luteal phase 
of the cycle (pre- and post- ovulation respectively). The day of ovulation was estimated based on 
the changes in estradiol to progesterone ratio. The moving average was calculated for the missing 
values of the differences in urine concentration for estradiol and progesterone. The cycle was 
considered ovulatory when PdG daily values were three or more times higher in comparison to the 
baseline for at least three days. Negative numbers were given to the follicular phase, and positive 
numbers were given to the luteal phase with “day 0” being the estimated day of ovulation.  
Dependent variable indices consisted of 4 main groups: follicular anxiety, mid-cycle 
anxiety, luteal anxiety, and whole cycle anxiety. Normality of distribution was ensured for the 
dependent variable by using natural logarithms to calculate for single values and E1G mean indices 
where necessary. Two outliers were removed from the dependent variable (anxiety distribution) 
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with significant increase of anxiety above 3 standard deviations. The independent variables for 
E1G and PdG consisted of 6 hormonal indices. Hormonal indices for E1G consisted of 4 main 
groups of E1G values: during the cycle, follicular, luteal, and mid-cycle phases. Hormonal indices 
for PdG consisted of 2 main groups of PdG values: during the luteal and mid-luteal phase of the 
cycle. Average E1G values during the cycle were grouped by quartiles (low, moderate, high, and 
very high values) and median (low and high) of the distribution. PdG values during the luteal phase 
were grouped by quartiles (low, moderate, high, and very high values) and median (low and high) 
of the distribution.  
 
2.5 Statistical Analysis  
The present study explored possible associations between the ovarian steroid hormones, estradiol 
and progesterone, and anxiety levels. This was achieved by investigating within-subject effects the 
between-subject effects of grouped E1G and PdG values during different phases of the menstrual 
cycle. Alpha level for the determination of statistical significance was set at α = 0.05. SPSS 
software and JASP software were used for data analysis. Internal validity for the STAI was 
assessed using Cronbach’s Alphas. All ANOVA analyses accounted for violation of sphericity and 
reported corrections where applicable. 
Anxiety levels were compared between four groups of E1G and PdG. Anxiety scores were 
taken from all 18 days of anxiety profiles throughout the whole cycle, the first 9 days of anxiety 
profiles comprising the follicular phase, the 5 days of anxiety profiles during the periovulatory 
period, and the last 8 days of anxiety profiles comprising the luteal phase of the cycle. The 
groupings assisted in direct comparisons between the means of groups of anxiety with groups of 
hormones. 
Multiple one-way repeated measures (ANOVA) analyses were conducted to assess within-
subjects factor of anxiety, the dependent variable, and the between-subject factors, the E1G values 
based on group indices of the hormone. This allowed for comparisons of low, medium, high, and 
very high groups of E1G for anxiety scores during the cycle, the follicular phase, the mid-cycle 
phase, and the luteal phase. It also aided in comparing low and high groups of E1G with anxiety 
scores during the cycle and the follicular phase. Other repeated measures (ANOVA) analyses were 
performed to explore within-subjects factor of anxiety and between-subject factors of PdG during 
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the luteal phase and mid-luteal phase based on grouped PdG values according to quartiles and 
median values of PdG distribution. This allowed for the comparison of low, medium, high, and 
very high groups of PdG with anxiety levels during the luteal phase and the mid-cycle phase.  
 
3. Results 
3.1 Descriptive statistics of participants and internal consistency of STAI measure 
Table 1 presents descriptive statistics of women participating in the present study. The participant 
(n = 106) mean age was 29.60 (SD = 3.59), mean BMI was 22.86 (SD = 3.62), and mean cycle 
length was 28.71 days (SD = 2.11). Table 2 presents the descriptive statistics for the independent 
variables estradiol (E1G) and progesterone (PdG) hormone levels during the follicular, mid-cycle, 
and luteal, mid-luteal phases, as well as during the whole cycle. The table also demonstrates the 
dependent variable of anxiety scores during the follicular, mid-cycle, and luteal phases, and the 
whole cycle. 
Table 1 
Participant age, BMI, and cycle length 
   N Minimum Maximum     Mean               SD 
Age 106       24.09                   38.35               29.60     3.59   
BMI 106              16.08                  33.50               22.86 3.62         
Cycle length 106             24                       35                28.71                  2.11  
 
 
 
Table 2 
E1G, PdG, and anxiety means and standard deviations during the follicular, mid-cycle, luteal 
phases and entire cycle  
  
Follicular            
M (SD) 
Mid-cycle                   
M (SD) 
Luteal                     
M (SD) 
Mid-luteal        Cycle Average               
M (SD)              M (SD) 
Estradiol 
83.36 (74.03) 127.49 (124.31)    90.47 (85.93)       -    86.93 (77.07) 
Progesterone  
         -           -                   5.51 (2.68)         6.77 (3.01)         - 
Anxiety 
  38.43 (5.89)  38.87 (7.97)          39.89 (6.47)           -     39.89 (6.47) 
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Alpha coefficients for the STAI scores for both state and trait scales indicated high internal 
consistency with α = .88 and ranged between .84 and .91. A Shapiro-Wilk’s test (p> .05)  (Shapiro 
& Wilk, 1965; Razali & Wah, 2011), and a visual inspection of the dependent variable histograms 
showed that the anxiety scores were not normally distributed for follicular anxiety with p = .000 
(SE = .668) and cycle anxiety with p = .034 (SE = 0.801). Scores were normally distributed for 
mid-cycle anxiety during the mid-cycle phase with p = .055 (SE = .802) and luteal anxiety with    
p = .077 (SE = .714). After two outliers which increased anxiety scores by more than 3 SD were 
removed from the data set, tests of normality of the dependent variable were inspected again and 
normal distribution was observed for follicular anxiety with p = .579 (SE = .583) and cycle anxiety 
with p = .869 (SE = 0.549). Figures 1-4 show normal distribution of the dependent variable of 
follicular anxiety, mid-cycle anxiety, luteal anxiety, and whole cycle anxiety. 
 
Figure 1 
Follicular Anxiety Histogram 
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Figure 2 
Mid-cycle Anxiety Histogram 
 
Figure 3 
Luteal Anxiety Histogram 
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Figure 4 
Cycle Anxiety Histogram 
 
 
3.2 Anxiety and estradiol (E1G) 
 
3.2.1 Anxiety during the whole cycle  
A repeated measures one-way ANOVA with a Greenhouse-Geisser correction determined that 
there was no within-subjects consistent effect of cycle day F(36.05, 937.31) = 0.890, p = 0.656 
and no between-subjects effect of E1G cycle groups (F(3, 78) = 0.524, p = 0.667) on anxiety level 
throughout the whole cycle. Comparisons of daily anxiety profiles over the whole cycle based on 
median values (high and low) of estradiol with  Greenhouse-Geisser corrections revealed similarly: 
no significant within-subjects effect of cycle day (F(12.14, 971.17) = 1.549, p = 0.100), as well as  
no significant between-subjects effect of E1G groups (F(1, 80) = 2.349, p = 0.996) on anxiety level 
throughout the cycle.  
 
3.2.2 Anxiety during the follicular phase 
A repeated measures one-way ANOVA compared daily anxiety profiles during the follicular phase 
grouped by quartiles (low, medium, high, very high) with anxiety profiles. Greenhouse-Geisser 
correction determined that there was no within-subjects effect of cycle day (F(20.291, 595.193) = 
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0.832, p = 0.676) on anxiety level, while also showing no significant effect of between-subjects of 
grouped E1G (F(3, 88) = 1.042, p = 0.378). Another repeated measures ANOVA with Huynh-
Feldt  corrections comparing daily anxiety profiles during the follicular phase based on median 
groups of E1G demonstrated no significant within-subjects effect of cycle day (F(6.769, 609.188) 
= 1.542, p = 0.153) on anxiety level and no significant between-subjects effect of E1G groups 
(F(1, 90) = 1.301, p = 0.257).  
 
3.2.3 Anxiety during the mid-cycle phase  
A repeated measures one-way ANOVA compared daily anxiety profiles during the mid-cycle 
phase grouped by quartiles (low, medium, high, very high) with anxiety profiles. The result 
determined that there was no within-subjects effect of cycle day (F(12, 372) = 1.303, p = 0.214) 
on anxiety level, while also showing no significant effect of between-subjects of grouped E1G 
(F(3, 93) = 0.290, p = 0.832). Another repeated measures ANOVA compared daily anxiety profiles 
during the mid-cycle phase grouped by median (low and high) with anxiety profiles. The results 
showed no statistically significant within-subjects effect of cycle day (F(4, 380) = 2.238, p = 0.064) 
on anxiety level and no significant between-subjects effect of E1G groups (F(1, 95) = 0.618,             
p = 0.434).  
 
3.2.4 Anxiety during the luteal phase  
A repeated measures one-way ANOVA compared daily anxiety profiles during the luteal phase 
grouped by quartiles (low, medium, high, very high) with anxiety profiles. Huynh-Feldt 
corrections determined that there was no within-subjects effect of cycle day (F(17.333, 502.666) 
= 0.918, p = 0.554) on anxiety level, while also showing no significant effect of between-subjects 
of grouped (E1G (F(3, 87) = 0.271, p = 0.846). Another repeated measures ANOVA with Huynh-
Feldt  corrections comparing daily anxiety profiles during the follicular phase based on median 
groups of E1G demonstrated no significant within-subjects effect of cycle day (F(5.809, 516.987) 
= 1.248, p = 0.281) on anxiety level and no significant between-subjects effect of E1G groups 
(F(1, 89) = 0.115, p = 0.735).  
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3.3 Anxiety and Progesterone (PdG) 
 
3.3.1 Anxiety during the luteal phase 
A repeated measures one-way ANOVA was performed to compare the luteal PdG grouped by 4 
groups (low, medium, high, very high) and daily anxiety profiles. Greenhouse-Geisser corrections 
demonstrated no significant within-subjects effect of cycle day (F(36.253, 930.482) = 1.331, p = 
.093) on anxiety level. There was also no significant between-subjects effect of PdG groups (F(3, 
77) =.291, p = 0.832). Another repeated measures one-way ANOVA comparing anxiety during 
the luteal phase grouped by 2 PdG groups (high and low) was conducted. Greenhouse-Geisser 
corrections for within-subjects effect of cycle day anxiety approached significance with F(12.088, 
954.917) = 1.709, p = 0.059. Between-subject effects of PdG cycle groups on anxiety was not 
significant (F(1, 79) = 0.245, p = 0.622).  
 
3.3.2 Anxiety during the mid-cycle phase 
Lastly, a repeated measures one-way ANOVA comparing luteal PdG grouped by 2 cycle groups 
(high and low) with anxiety during the mid-cycle phase. Huynh-Feldt corrections demonstrated no 
significant within-subjects effect of cycle day (F(7.103, 646.335) = 1.104, p = 0.358) on anxiety 
level. There was also no significant between-subjects effect found of PdG groups (F(1, 91) = 0.000, 
p = 0.997).  
 
4. Discussion 
The present study assessed the relationships between estradiol, progesterone, and anxiety levels in 
women over the course of their menstrual cycle phases. This was achieved by comparing the 
within-person cyclical changes and the between-person average hormone differences in groups of 
hormones. The present research did not confirm the two main hypotheses stating that women’s 
levels of estradiol and progesterone during the cycle phases are associated with their reported 
anxiety levels. First, there was no convincing evidence to support the first hypothesis stating that 
estradiol is significantly associated with anxiety scores during the whole cycle, the follicular phase, 
the mid-cycle phase, and the luteal phase. One finding on the comparison between anxiety and 
estradiol during the mid-cycle phase stood out as it neared statistical significance. However, the 
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finding was not statistically significant enough to suggest that cycle day during the mid-cycle 
phase would have an effect on anxiety. In other words, no effect of estradiol on anxiety was 
observed, thus supporting existing animal and human research (Gleason et al., 2015; Zeidan et al. 
2011; Lund et al. 2005). 
Second, there was no clear evidence to support the second hypothesis that progesterone is 
significantly associated with anxiety scores during the luteal and during the mid-cycle phase. The 
within-subjects effect of cycle day on progesterone during the luteal phase demonstrated a 
tendency toward significance, which would suggest that anxiety scores throughout the luteal phase 
are associated with progesterone levels. If more statistically significant, this result would be in line 
with the study by the claim by Galeeva et al. (2007) suggesting that progesterone levels may 
upregulate levels of anxiety. However, this finding was determined as insignificant based on 
significance criteria set by the researcher. Therefore, it is concluded that this finding supports 
previous animal research indicating that there is no sufficient evidence that progesterone and 
higher levels of anxiety during the follicular phase are associated (Frye and Walf, 2004; Walf and 
Frye, 2005). 
 
Estradiol and anxiety 
The findings that estradiol showed no significant effect on anxiety supports previous animal and 
human studies where estradiol was reported to have an anxiolytic, anxiety-reducing, effect (Frye 
and Walf, 2014; Walf and Frye, 2005; Borrow and Handa, 2017). In one particular study, it was 
observed that estradiol injections in rodents had both an anxiolytic and an anxiogenic effect 
depending on the type of selective agonist administered (Lund et al., 2005). Complex brain 
mechanisms should be considered in relevance to the present study as a way to explain this null-
finding. Perhaps one explanation is that different types of estrogen receptors are utilized during 
administration of estradiol. For example, current studies have observed effects suggesting that the 
selective agonist ERβ may generate anxiolytic effects, whereas the selective agonist ERα may have 
a mostly anxiogenic effect (Borrow and Handa, 2017). According to Lund et al. (2005), the 
different type of selective estradiol agonist used to inject rodents may explain why estradiol both 
caused and decreased anxiety. Understanding which receptor of estrogen is being utilized may lead 
us to understand how it impacts anxiety. In other words, the different receptors of estradiol in the 
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brain can increase or decrease anxiety. Further research could focus on finding which receptor 
subtypes increase or decrease anxiety and explore how the receptors modulate anxiety in women 
in order to improve the effectiveness anxiety treatment.  
Another explanation as to why naturally cycling estradiol was not found to be associated 
with anxiety levels throughout the cycle could be explained through the HPA axis and its response 
to anxiety (Borrow and Handa, 2017). According to Frye and Walf (2004), the responsiveness of 
the hypothalamic and pituitary axis may have a role in estradiol’s effect on anxiety. Estrogen 
receptors have been linked to stress responsivity as ERα and ERβ may mediate anxiety-like 
behavior based on their actions on the HPA axis (Borrow and Handa, 2017). When considering 
estrogen receptors and the HPA axis response, it can be speculated that these factors may influence 
how estradiol impacts anxiety during the menstrual cycle, and therefore, further studies should 
explore these components in humans and rodents.  
 
Progesterone and anxiety 
The null-findings were unexpected, since one of the few human studies on progesterone and 
anxiety by Reynolds et al. (2018) provided convincing evidence that women with higher average 
progesterone levels across their cycles had higher levels of anxiety. Although Reynold’s evidence 
was not supported by the present study, it does not explain the claim that higher levels of anxiety 
and irritability are observed during the luteal phase as reported by other researchers (Davydov et 
al., 2005), a time during which progesterone significantly drops.  
Perhaps the present result can be explained by research by Galeeva et al. (2007) claiming 
that the fluctuating levels of progesterone is not what is associated with anxiety, but rather the 
levels of blood-ratio concentrations of estradiol and progesterone at any given point during the 
cycle which determines anxiety levels. As reported by Graham, Ash, and Den (2017), estradiol 
and progesterone levels are highly associated with each other throughout the cycle as they co-
fluctuate (Graham, Ash, & Den, 2017). The relationship between the two hormones is subject to 
few human studies (Graham, Ash, & Den, 2017). The implication here is that the progesterone’s 
ratio to estradiol during the different cycle phases is what may cause women to feel anxious instead 
of the hormone levels by themselves in comparison to anxiety. Future research on associations 
between the blood ratio progesterone should consider how this hormone interacts with estradiol, 
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and how the blood-ratio concentration of these two hormones potentially with anxiety levels 
throughout the menstrual cycle.  
Furthermore, questions have been raised regarding the observation that progesterone may 
inhibit the effects of estrogen (Baudry, Bi, & Aguirre, 2013). Understanding the intricate 
interactions between the two hormones in complex pathways and expression of various receptors 
(Baudry et al., 2013), as well as how the hormones interact with the HPA axis (Walf & Fyre, 2005), 
could be the key to explaining how they impact anxiety. The conflicting results consistently seen 
in current research expresses our limited understanding of the complex roles of hormones and their 
relationship with the human brain and human mood. Moreover, our studies are largely based on 
animal studies, particularly rodents. This demonstrates the necessity to continue investigating the 
associations between hormones and anxiety in humans, as was explored in the current study.  
 
General Discussion  
The null-findings of the present study reveal that we can infer that there are no statistically 
significant associations between hormone levels and anxiety during different cycle phases. 
However, it is possible that design and methodological limitations could explain the present 
findings. Several limitations of the study should be noted. First, the study did not control for 
possible confounding factors in the current design. As state and trait anxiety are highly correlated, 
this could be a potentially confounding factor. It is not clear how much of the present results may 
be attributed to other factors (e.g. emotional reactivity or BMI). Future studies should consider 
controlling for possible confounding factors, such as emotional or physical characteristics or 
features, by employing an ANCOVA design.  
Second, the present study did not investigate the extent to which hormones co-fluctuate 
and how anxiety levels are related together during the different cycle phases. It is also important 
to mention that some authors suggest that neither progesterone nor estradiol alone are determining 
factors of anxiety state, but rather it is their quantitative blood concentration ratio that determines 
anxiety (Galeeva et al., 2007). This could have different implications on how we study estradiol 
and progesterone, as it suggests that our understanding of how these two hormones interact and 
impact affect in humans is very limited. In order to account for this important distinction, 
correlational and regression analysis could be used in future investigations on this topic. These 
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analyses may be useful to assess the direction of hormone and anxiety relationships, and to help 
estimate the relationships among the independent and dependent variables. Thus, a different design 
could be better suited to help us understand how cycle phases and hormones are associated with 
one another, and perhaps even yield different results than the present study.  
Third, hormone collection and measurements reflected levels of estradiol and progesterone 
only during that particular time of day (morning). Hormones fluctuate often and rapidly, therefore 
collecting daily samples could improve the accuracy of the hormone levels by giving a more 
consistent measurement. The present study only measured 18 days throughout the cycle, which is 
on average 28 days long, ranging between 24 and up to 35 days as observed in the current sample. 
Acquiring daily samples could improve our understanding of hormone fluctuations. Additionally, 
women were studied over the course of only one menstrual cycle. There is evidence that women’s 
estradiol and progesterone levels vary across cycles (Jasienska et al., 2017). Future studies may 
attempt to assess women’s hormonal levels across multiple menstrual cycles in order to understand 
the fluctuation of levels in relation to anxiety across longer periods of time.  
Fourth, one should interpret the present results with caution as they may not be 
generalizable to most women. Although the study sample was heterogenous, it solely represents 
healthy women of reproductive age in this geographic, sociocultural region. These results should 
be generalized with caution to women of other ethnic and cultural origins, different weight (i.e. 
underweight or overweight/obese weight), or women of certain socio-economic status where 
anxiety levels could be higher. 
This study contributes to a growing body of research on the associations between estradiol, 
progesterone, and subjectively reported anxiety levels. Although there were no clinically 
significant findings suggesting that estradiol and progesterone impact anxiety throughout the 
menstrual cycle and its phases, this has important implications regarding anxiety experienced by 
women. Perhaps anxiety is influences by factors such as hormone blood-ratio concentrations rather 
than the fluctuations of the hormones. Moreover, anxiety could possibly be determined by the 
hormone interaction with the HPA axis. It is possible that anxiety is simply not influenced by 
estradiol or progesterone fluctuations during the cycle. Therefore, further studies should consider 
exploring the relationship between estradiol and progesterone, the neuro-receptors utilized in the 
brain when these hormones are activated, and the hormones’ ratios during different cycle phases. 
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Future research may also consider exploring women’s cycles for longer periods of time as the 
explanation for the current findings could be in the variations from cycle to cycle. In conclusion, 
the present study contributed the findings that estradiol, progesterone, and self-reported anxiety 
levels throughout women’s menstrual cycle phases are not associated together, highlighting the 
importance for future investigations into this complex and fascinating topic.  
The findings discussed here have important implications for women in today’s society. As 
suggested by Spielberger et al. (1983), we are living in “an age of anxiety”. Anxiety disorders are 
debilitating to women as their symptoms can cause various health issues, work absence, and 
reproductive challenges (Booth et al., 2016). Given the present results and all the studies on this 
topic thus far, it is still unclear how to effectively treat these disorders or how to prevent them in 
women. It is essential that future research continues to investigate how to alleviate the 
psychological, emotional, and physical burden of anxiety from the lives of women.  
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